Complimentary Registration Available for Hot Topic Discussion on CCP Use in Immunosuppressed Patients with COVID-19

AABB’s next Hot Topic Discussion will explore the use of high-titer COVID-19 convalescent plasma (CCP) in immunocompromised patients with COVID-19. This complimentary program will take place from 2 to 3:15 p.m. ET on Thursday, June 30.

Approximately seven million (or 2.7%) American adults are immunocompromised and are, therefore, more likely to experience severe and prolonged illness from COVID-19 infection. Evidence suggests that when other options have proven to be ineffective, treatment with high-titer CCP may provide an effective therapeutic alternative in this patient population.

In this complimentary program, experts will review the data around the use of high-titer CCP collected from donors with recent breakthrough COVID-19 infections and discuss which patients can most benefit from CCP therapy. The program will also examine the effectiveness of CCP compared with other therapies and discuss current guidance for FDA-permitted use. An extended question and answer period will follow the presentations.

Registration for this program is complimentary but required in order to attend.